VanEck Vectors Pharmaceutical ETF (PPH) - NYSEARCA
  • Apr. 22, 2014, 12:14 PM
    | Apr. 22, 2014, 12:14 PM
  • Dec. 14, 2011, 7:50 AM
    Fitch is establishing a negative 2012 outlook for pharmaceutical companies, arguing soft demand, patent expirations, and government spending cuts will take a toll on the industry; the patent expirations (I, II, III) are seen affecting LLY, BMY, and PFE the most. Fitch also sees pharmas responding to these challenges by stepping up their M&A activity.
    | Dec. 14, 2011, 7:50 AM
PPH Description
VanEck Vectors Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
See more details on sponsor's website
Sector: Healthcare
Country: United States
ETF Hub
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub